A nationwide Guillain-Barré syndrome epidemiological study in Spain during the COVID-19 years
Blanco-Ruiz, M. (Hospital Universitario Torrecárdenas (Almeria, Andalusia))
Martín-Aguilar, Lorena (Institut de Recerca Sant Pau)
Caballero-Ávila, Marta (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Lleixà, Cinta (Institut de Recerca Sant Pau)
Pascual-Goñi, Elba (Institut de Recerca Sant Pau)
Collet Vidiella, Roger (Institut de Recerca Sant Pau)
Tejada-Illa, Clara (Institut de Recerca Sant Pau)
Turon-Sans, Janina (Institut de Recerca Sant Pau)
Carbayo Viejo, Álvaro (Institut de Recerca Sant Pau)
Llansó, Laura (Institut de Recerca Sant Pau)
Cortés-Vicente, Elena (Institut de Recerca Sant Pau)
Amaya Pascasio, L. (Hospital Universitario Torrecárdenas (Almeria, Andalusia))
Querol, Luis (Institut de Recerca Sant Pau)
Universitat Autònoma de Barcelona

Data:	2024
Resum:	Background and purpose: The purpose was to perform a nationwide epidemiological study of Guillain-Barré syndrome (GBS) in Spain, analysing background incidences and seasonal variation and trying to identify incidence changes during the coronavirus disease 2019 (COVID-19) years. Methods: This was an observational study collecting all GBS diagnoses from the National Epidemiological Surveillance Network collected by the Ministry of Health. Patients discharged with GBS as the main diagnosis and admitted during 2018-2021 were included. Data on the incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections were obtained from the National Epidemiology Centre. Results: In total, 3147 cases were included, 832 in 2018, 861 in 2019, 670 in 2020 and 784 in 2021. Nationwide hospital incidence was 1. 78 in 2018, 1. 71 in 2019, 1. 41 in 2020 and 1. 66 in 2021, with an increased frequency in males, the elderly population and in the winter season. Eleven per cent of GBS patients needed ventilatory support. GBS and SARS-CoV-2 incidences did not correlate with one another (r = -0. 29, p = 0. 36). GBS incidence decreased during 2020 and during the COVID-19 lockdown period in comparison to the same months of 2018-2019. Conclusions: The incidence of GBS in Spain is similar to that of other countries. Despite prior reports describing a significant increase in COVID-19-associated GBS in Spain, a significant drop of GBS incidence during the SARS-CoV-2 pandemic was detected, probably due to prevention measures.
Ajuts:	Instituto de Salud Carlos III PI22/00387
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	COVID-19 ; Guillain-Barré syndrome ; Spain ; Epidemiology ; Vaccines
Publicat a:	European Journal of Neurology, Vol. 31 Núm. 12 (december 2024) , p. e16439, ISSN 1468-1331

DOI: 10.1111/ene.16439
PMID: 39132887

7 p, 853.6 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats